ERO1A and cancer: In conclusion, our findings suggest that among oxidizing enzymes, ERO1α is predominantly activated only under abnormal conditions such as hypoxia and contributes to cancer progression, and further that ERO1α might serve as an optimal target for cancer therapy because ERO1α suppression could inhibit integrin-related signalling specifically in the cancer microenvironment.